Status:

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Lead Sponsor:

Zealand Pharma

Collaborating Sponsors:

Parexel

Conditions:

Overweight

Type 2 Diabetes

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.

Eligibility Criteria

Inclusion

  • Main
  • Male or female participants with body mass index (BMI) ≥27.0 kg/m2.
  • Diagnosed with type 2 diabetes ≥180 days prior to the day of screening.
  • Treated with metformin with or without sodium-glucose cotransporter 2 inhibitors. Treatment should be stable (same drug\[s\], dose, and dosing frequency) for at least 90 days prior to screening.
  • Main

Exclusion

  • Severe hypoglycemia within 6 months prior to screening or history of hypoglycemia unawareness.
  • Receipt of any other glucose-lowering drug than those listed in the inclusion criterion within 90 days prior to screening.
  • A self-reported change in body weight \>5% within 90 days prior to screening, irrespective of medical records.
  • Treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 90 days prior to screening.
  • Previous or planned (during the trial period) obesity treatment with surgery or a body weight loss device. However, liposuction or surgical removal of fat depots more than 1 year prior to screening or device-based interventions (e.g., sleeve, banding, or similar) that have been removed more than 6 months prior to screening, are allowed.
  • Obesity due to endocrine disorders or genetic syndromes.

Key Trial Info

Start Date :

April 22 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 13 2026

Estimated Enrollment :

221 Patients enrolled

Trial Details

Trial ID

NCT06926842

Start Date

April 22 2025

End Date

August 13 2026

Last Update

December 15 2025

Active Locations (48)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (48 locations)

1

Cullman Clinical Trials - Family Medicine

Cullman, Alabama, United States, 35055

2

AZ Endocrine Institute

Chandler, Arizona, United States, 85224

3

Elite Clinical Studies, LLC

Phoenix, Arizona, United States, 85018

4

M3 Wake Research, Tucson Neuroscience Research, LLC

Tucson, Arizona, United States, 85710